Profil
Susanna G.
High is currently the Chief Executive Officer at Paragon Therapeutics, Inc. She previously held positions as the Director-Corporate Strategy at Millennium Pharmaceuticals, Inc. from 2001 to 2007, the Chief Operating Officer at bluebird bio, Inc. from 2016 to 2019, and the SVP-Strategy & Business Integration at Alnylam Pharmaceuticals, Inc. from 2007 to 2016.
Prior to that, she worked as a Management Consultant at Accenture LLC from 1996 to 2001.
Ms. High also served as the Chief Operating Officer at Dyne Therapeutics, Inc. from 2020 to 2024.
She graduated from the University of Bocconi and holds an MBA from MIT Sloan School of Management, which she received in 1996.
Aktive Positionen von Susanna High
| Unternehmen | Position | Beginn |
|---|---|---|
Paragon Therapeutics, Inc.
Paragon Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Vorstandsvorsitzender | 21.11.2024 |
Ehemalige bekannte Positionen von Susanna High
| Unternehmen | Position | Ende |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Geschäftsführer | 01.10.2024 |
| GENETIX BIOTHERAPEUTICS, INC. | Geschäftsführer | 04.01.2019 |
| ALNYLAM PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.06.2008 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Corporate Officer/Principal | 01.01.2007 |
Accenture LLC
Accenture LLC Miscellaneous Commercial ServicesCommercial Services Provides financial and investment services | Corporate Officer/Principal | 01.01.2001 |
Ausbildung von Susanna High
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
bluebird bio, Inc.
bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
University of Bocconi
University of Bocconi Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Accenture LLC
Accenture LLC Miscellaneous Commercial ServicesCommercial Services Provides financial and investment services | Commercial Services |
MIT Sloan School of Management
MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat muscle diseases | Health Technology |
Paragon Therapeutics, Inc.
Paragon Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
















